{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:02:39Z","timestamp":1792450959565,"version":"4.5.0"},"reference-count":86,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the state program \u201cScientific and technological development of the Sirius Federal Territory\u201d","award":["30-03"],"award-info":[{"award-number":["30-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The escalating global burden of antimicrobial resistance constitutes a public health crisis. The World Health Organization reports that epidemiological models project 10 million deaths attributable to this issue annually by 2050. Among resistant pathogens, metallo-\u03b2-lactamase (MBL)-producing organisms represent a clinical challenge, given their consistent association with high rates of morbidity and mortality. This review summarizes effective treatment options against MBL-producing Enterobacterales. In clinical practice, a pragmatic therapeutic decision rule can be applied: when aztreonam\u2013avibactam (ATM\u2013AVI) is accessible and in vitro susceptibility is confirmed, it should be regarded as the preferred targeted regimen for infections caused by MBL-producing Enterobacterales. In settings where ATM\u2013AVI is unavailable, the combination of ceftazidime\u2013avibactam with aztreonam (CAZ\u2013AVI + ATM) remains the treatment of choice, an approach endorsed by current recommendations from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Critical evaluation of the published evidence is essential to inform the selection of optimal therapeutic regimens for affected patients. Novel antimicrobial agents are currently under clinical development and may broaden the therapeutic toolkit in the near future.<\/jats:p>","DOI":"10.3390\/ijms27125320","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:49:51Z","timestamp":1781257791000},"page":"5320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Options for Metallo-Beta-Lactamase-Producing Enterobacterales in the Era of Increasing Resistance"],"prefix":"10.3390","volume":"27","author":[{"given":"Anastasia","family":"Golovina","sequence":"first","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0843-3742","authenticated-orcid":false,"given":"Fedor","family":"Antipin","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Khalymbadzha","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7912-3282","authenticated-orcid":false,"given":"Olga","family":"Terina","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8659-4585","authenticated-orcid":false,"given":"Daniil","family":"Yakovlev","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4218-0406","authenticated-orcid":false,"given":"Elena","family":"Fedina","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9573-4183","authenticated-orcid":false,"given":"Roman","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Translational Medicine Research Center, Sirius University of Science and Technology, Olympic Ave. 1, Federal Territory \u201cSirius\u201d, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e71077","DOI":"10.1002\/hsr2.71077","article-title":"The Global Challenge of Antimicrobial Resistance: Mechanisms, Case Studies, and Mitigation Approaches","volume":"8","author":"Nazir","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jgar.2025.08.014","article-title":"Prevalence, Clinical Characteristics, and Mortality Impact of Metallo-\u03b2-Lactamase-Producing Enterobacter Cloacae Complex Infections: A Retrospective Cohort Study","volume":"45","author":"Lee","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3947\/ic.2024.0038","article-title":"Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections","volume":"56","author":"Park","year":"2024","journal-title":"Infect. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1039\/D5MD00035A","article-title":"Navigating the Complexities of Drug Development for Metallo-\u03b2-Lactamase Inhibitors","volume":"16","author":"Reddy","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A Prioritisation Study to Guide Research, Development, and Public Health Strategies against Antimicrobial Resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sava, M., Vintila, B.I., Bereanu, A.S., Fratila, A.M., and Codru, I.R. (2025). Lessons from Four Years (2021-2024) of Klebsiella pneumoniae Resistance Surveillance Epidemiological Trends in a Romanian Intensive Care Unit. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080825"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Olaniyan, T.O., Mart\u00ednez-V\u00e1zquez, A.V., Escobedo-Bonilla, C.M., L\u00f3pez-Rodr\u00edguez, C., Huerta-Lu\u00e9vano, P., Castrej\u00f3n-S\u00e1nchez, O., de La Cruz-Flores, W.L., Cede\u00f1o-Castillo, M.J., de Luna-Santillana, E.d.J., and Cruz-Hern\u00e1ndez, M.A. (2025). The Prevalence of ESKAPE Pathogens and Their Drug Resistance Profiles in Aquatic Environments Around the World. Microbiol. Res., 16.","DOI":"10.3390\/microbiolres16090201"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Elshobary, M.E., Badawy, N.K., Ashraf, Y., Zatioun, A.A., Masriya, H.H., Ammar, M.M., Mohamed, N.A., Mourad, S., and Assy, A.M. (2025). Combating Antibiotic Resistance: Mechanisms, Multidrug-Resistant Pathogens, and Novel Therapeutic Approaches: An Updated Review. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030402"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1021\/acsinfecdis.0c00001","article-title":"Multitarget Approaches against Multiresistant Superbugs","volume":"6","author":"Gray","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108550","DOI":"10.1016\/j.pharmthera.2023.108550","article-title":"Multitarget Antibacterial Drugs: An Effective Strategy to Combat Bacterial Resistance","volume":"252","author":"Feng","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40121-021-00412-y","article-title":"Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap","volume":"10","author":"Yahav","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14737167.2021.1964960","article-title":"Cost-Utility Analysis of Ceftazidime-Avibactam versus Colistin-Meropenem in the Treatment of Infections Due to Carbapenem-Resistant Klebsiella pneumoniae in Colombia","volume":"22","author":"Lemos","year":"2022","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12962-023-00454-8","article-title":"Cost-Effectiveness Analysis of Ceftazidime Avibactam versus Colistin in Carbapenem-Resistant Enterobacteriaceae in Iran","volume":"21","author":"Goudarzi","year":"2023","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40273-025-01528-6","article-title":"Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-\u03b2-Lactamase (MBL)-Producing Enterobacterales in Italy","volume":"43","author":"Falcone","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1039\/D2MD00465H","article-title":"Siderophore Conjugates to Combat Antibiotic-Resistant Bacteria","volume":"14","author":"Rayner","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37201\/req\/s02.02.2022","article-title":"Mechanism of Action of Cefiderocol","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","article-title":"US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja\u00ae)","volume":"72","author":"Naseer","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00063-022-00925-5","article-title":"Clinical experience using cefiderocol","volume":"118","author":"Witzke","year":"2023","journal-title":"Med. Klin. Intensivmed. Notfmed."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Baicus, A., Sisu, V.D., Tatar, A.D., Gherghel, A., Iacob, D.G., Pop, C.S., and Cirstoiu, C.F. (2025). In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania. Antibiotics, 14.","DOI":"10.3390\/antibiotics14111113"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Padovani, M., Bertelli, A., Corbellini, S., Piccinelli, G., Gurrieri, F., and De Francesco, M.A. (2023). In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040785"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In Vitro Activity of Cefiderocol against Carbapenemase-Producing and Meropenem-Non-Susceptible Gram-Negative Bacteria Collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tristancho-Bar\u00f3, A., L\u00f3pez-Calleja, A.I., Milagro, A., Ariza, M., Vi\u00f1eta, V., Fortu\u00f1o, B., L\u00f3pez, C., Latorre-Mill\u00e1n, M., Clusa, L., and Badenas-Alzugaray, D. (2025). Mechanisms of Cefiderocol Resistance in Carbapenemase-Producing Enterobacterales: Insights from Comparative Genomics. Antibiotics, 14.","DOI":"10.20944\/preprints202505.2477.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus Standard Therapy for Hospital-Acquired and Health-Care-Associated Gram-Negative Bacterial Bloodstream Infection (the GAME CHANGER Trial): An Open-Label, Parallel-Group, Randomised Trial","volume":"26","author":"Paterson","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e01582-20","DOI":"10.1128\/AAC.01582-20","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria","volume":"64","author":"Mushtaq","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Molecularly Characterized, Carbapenem-Non-Susceptible Gram-Negative Bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_30","unstructured":"(2026, March 27). Clinical Breakpoint Tables. Available online: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-tables\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","article-title":"In Vitro Resistance Development Gives Insights into Molecular Resistance Mechanisms against Cefiderocol","volume":"77","author":"Kriz","year":"2024","journal-title":"J. Antibiot."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkn165","article-title":"Tigecycline for the Treatment of Multidrug-Resistant (Including Carbapenem-Resistant) Acinetobacter Infections: A Review of the Scientific Evidence","volume":"62","author":"Karageorgopoulos","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and Safety of Tigecycline for the Treatment of Severe Infectious Diseases: An Updated Meta-Analysis of RCTs","volume":"39","author":"Shen","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijantimicag.2009.05.004","article-title":"Tigecycline-Induced Acute Pancreatitis: Case Report and Literature Review","volume":"34","author":"Hung","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/87551225231211737","article-title":"Tigecycline and Hypoglycemia, When and How?","volume":"40","author":"Hakeam","year":"2024","journal-title":"J. Pharm. Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-Dose Tigecycline for the Treatment of Nosocomial Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.21037\/tau-20-959","article-title":"Efficacy and Safety of Tigecycline for Complicated Urinary Tract Infection: A Systematic Review","volume":"10","author":"Liu","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jiac.2024.02.007","article-title":"Monotherapy vs Combination Therapy in Patients with Klebsiella pneumoniae Bloodstream Infection: A Systematic Review and Meta-Analysis","volume":"30","author":"Li","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14744\/ejmo.2024.79645","article-title":"Escherichia Coli Bloodstream Infections and Associated Antibiotic Resistance Pattern in Hematological Malignancy Populations, A Global Systematic Review","volume":"8","author":"Jafarabadi","year":"2024","journal-title":"Eurasian J. Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/IDR.S505311","article-title":"Effectiveness of Omadacycline in a Patient with Chlamydia psittaci and KPC-Producing Gram-Negative Bacteria Infection","volume":"18","author":"Yang","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","article-title":"Ceftazidime-Avibactam","volume":"34","author":"Matesanz","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1128\/AAC.00897-16","article-title":"Interaction of Avibactam with Class B Metallo-\u03b2-Lactamases","volume":"60","author":"Abboud","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.18203\/2319-2003.ijbcp20254154","article-title":"In Vitro Assessment of Ceftazidime-Avibactam Combined with Aztreonam for Mitigating Antimicrobial Resistance in Clinical Isolates of Multidrug-Resistant Gram-Negative Bacilli","volume":"15","author":"Joemon","year":"2026","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100819","DOI":"10.1016\/j.ijmmb.2025.100819","article-title":"Unleashing the Potent Synergy of Ceftazidime-Avibactam and Aztreonam against Metallo-Beta-Lactamase Producing Enterobacterales in the Battle against Antibiotic Resistance. An in Vitro Study","volume":"54","author":"Rai","year":"2025","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-Avibactam Plus Aztreonam in Patients with Bloodstream Infections Caused by Metallo-\u03b2-Lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","first-page":"101175","article-title":"Mortality of Metallo-\u03b2-Lactamase-Producing Enterobacterales Bacteremias with Combined Ceftazidime-Avibactam plus Aztreonam vs. Other Active Antibiotics: A Multicenter Target Trial Emulation","volume":"49","author":"Huespe","year":"2025","journal-title":"Lancet Reg. Health Am."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mantzarlis, K., Manoulakas, E., Papadopoulos, D., Katseli, K., Makrygianni, A., Leontopoulou, V., Katsiafylloudis, P., Xitsas, S., Papamichalis, P., and Chovas, A. (2025). Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Klebsiella pneumoniae Resistant to All Beta-Lactame\/Beta-Lactamase Inhibitor Combinations. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080806"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s15010-023-02094-9","article-title":"Ceftazidime-Avibactam Alone or in Combination with Aztreonam versus Polymyxins in the Management of Carbapenem-Resistant Klebsiella pneumoniae Nosocomial Infections (CAPRI Study): A Retrospective Cohort Study from South India","volume":"52","author":"Sree","year":"2024","journal-title":"Infection"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam\u2013Avibactam: The Dynamic Duo against Multidrug-resistant Gram-negative Pathogens","volume":"44","author":"Bleick","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacterales Isolates Collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021","volume":"42","author":"Wise","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-Avibactam for the Treatment of Serious Infections Caused by Metallo-\u03b2-Lactamase-Producing Gram-Negative Pathogens: A Phase 3 Randomized Trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-Avibactam versus Meropenem for the Treatment of Serious Infections Caused by Gram-Negative Bacteria (REVISIT): A Descriptive, Multinational, Open-Label, Phase 3, Randomised Trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Comini, S., Boattini, M., Gaibani, P., and Bianco, G. (2026). Cefepime Combined with Late-Generation \u03b2-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK\/PD Characteristics, Clinical Evidence and Resistance Mechanisms. Antibiotics, 15.","DOI":"10.3390\/antibiotics15030263"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e0216121","DOI":"10.1128\/aac.02161-21","article-title":"In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain","volume":"66","author":"Bou","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-Taniborbactam in Complicated Urinary Tract Infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e0049325","DOI":"10.1128\/aac.00493-25","article-title":"Plasma and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Adult Participants","volume":"69","author":"Rodvold","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: Mechanism and Resistance","volume":"7","author":"Silver","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","article-title":"Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study","volume":"14","author":"Bodmann","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciae197","article-title":"Fosfomycin as a Potential Therapeutic Option in Nonsevere Infections Caused by Metallo-\u03b2-Lactamase-Producing Enterobacterales: Need for Evidence","volume":"80","author":"Falcone","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107134","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Intravenous Fosfomycin in Combination Regimens as a Treatment Option for Difficult-to-Treat Infections Due to Multi-Drug-Resistant Gram-Negative Organisms: A Real-Life Experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","article-title":"Evaluation of Colistin as an Agent against Multi-Resistant Gram-Negative Bacteria","volume":"25","author":"Li","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Aysert-Yildiz, P., \u00d6zgen-Top, \u00d6., \u015eent\u00fcrk, A.F., Kanik, S., \u00d6zger, H.S., and Dizbay, M. (2024). Polymyxin B vs. Colistin: The Comparison of Neurotoxic and Nephrotoxic Effects of the Two Polymyxins. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09759-2"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Shao, Z., Lu, L., Tang, S., Shi, K., Gong, F., and Liu, J. (2023). Ceftazidime\/Avibactam Combined with Colistin: A Novel Attempt to Treat Carbapenem-Resistant Gram-Negative Bacilli Infection. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08715-w"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s15010-024-02324-8","article-title":"Ceftazidime\/Avibactam versus Polymyxin B in Carbapenem-Resistant Klebsiella pneumoniae Infections: A Propensity Score-Matched Multicenter Real-World Study","volume":"53","author":"Zhuang","year":"2025","journal-title":"Infection"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhuang, H., Chen, Q., Wang, W., Qu, Q., Xu, W., Hu, Q., Wu, X., Chen, Y., Wan, Q., and Xu, T. (2025). The efficacy of polymyxin B in treating stroke-associated pneumonia with carbapenem-resistant Gram-negative bacteria infections: A multicenter real-world study using propensity score matching. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1413563"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103091","DOI":"10.1016\/j.jiph.2025.103091","article-title":"Comparative Analysis of Colistin and Polymyxin B Minimal Inhibitory Concentrations in Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa","volume":"19","author":"Huang","year":"2026","journal-title":"J. Infect. Public Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1021\/acsomega.3c00312","article-title":"Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance","volume":"8","author":"Dhanda","year":"2023","journal-title":"ACS Omega"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1021\/acsinfecdis.4c00136","article-title":"(Heteroarylmethyl)Benzoic Acids as a New Class of Bacterial Cystathionine \u03b3-Lyase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling","volume":"10","author":"Golovina","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The Urgent Need for Metallo-\u03b2-Lactamase Inhibitors: An Unattended Global Threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Huang, Y.-S., and Zhou, H. (2025). Breakthrough Advances in Beta-Lactamase Inhibitors: New Synthesized Compounds and Mechanisms of Action Against Drug-Resistant Bacteria. Pharmaceuticals, 18.","DOI":"10.20944\/preprints202501.0030.v1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e01076-20","DOI":"10.1128\/AAC.01076-20","article-title":"Pharmacodynamics of the Novel Metallo-\u03b2-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae","volume":"64","author":"Das","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e00203-21","DOI":"10.1128\/AAC.00203-21","article-title":"Novel Specific Metallo-\u03b2-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales","volume":"65","author":"Zalacain","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"ofac492.294","DOI":"10.1093\/ofid\/ofac492.294","article-title":"216. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-Lactamase Inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects","volume":"9","author":"Griffith","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e01852-25","DOI":"10.1128\/aac.01852-25","article-title":"Pharmacokinetics\/Pharmacodynamics of KSP-1007 in Combination with Meropenem against Carbapenemase-Producing Gram-Negative Bacteria in a Neutropenic Murine Thigh Infection Model","volume":"70","author":"Takemoto","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e70233","DOI":"10.1002\/mbo3.70233","article-title":"Reversing Antibiotic Resistance: Strategies From Adjuvants to Innovative Therapeutics","volume":"15","author":"Li","year":"2026","journal-title":"Microbiologyopen"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"108716","DOI":"10.1016\/j.ijid.2026.108716","article-title":"A Comparative Evaluation of Aztreonam-Avibactam and Ceftazidime-Avibactam Plus Aztreonam for Infections Due to MBL-Producing Enterobacterales","volume":"168","author":"Giuliano","year":"2026","journal-title":"Int. J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","article-title":"The Efficacy and Safety of Tigecycline for the Treatment of Bloodstream Infections: A Systematic Review and Meta-Analysis","volume":"16","author":"Wang","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4103\/jfmpc.jfmpc_1074_24","article-title":"Fosfomycin Susceptibility in Multidrug Resistant Uropathogens: A Retrospective Study in the Era of Antimicrobial Resistance","volume":"14","author":"Kaur","year":"2025","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e01281-22","DOI":"10.1128\/aac.01281-22","article-title":"In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program","volume":"67","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/infdis\/jiaf203","article-title":"Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens","volume":"232","author":"Watkins","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00397-20","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"20002","DOI":"10.1038\/s41598-022-16744-9","article-title":"Developing a New Sepsis Screening Tool Based on Lymphocyte Count, International Normalized Ratio and Procalcitonin (LIP Score)","volume":"12","author":"Liu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Mauri, C., Maraolo, A.E., Di Bella, S., Luzzaro, F., and Principe, L. (2021). The Revival of Aztreonam in Combination with Avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081012"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., and Poulakou, G. (2019). The \u201cOld\u201d and the \u201cNew\u201d Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. Front. Public Health, 7.","DOI":"10.3389\/fpubh.2019.00151"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Katsarou, A., Stathopoulos, P., Tzvetanova, I.D., Asimotou, C.-M., and Falagas, M.E. (2025). \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens, 14.","DOI":"10.3390\/pathogens14020168"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:54:43Z","timestamp":1781258083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":86,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125320"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125320","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}